Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
← catalyst calendarSponsored by Exelixis (industry) · EXEL — their whole pipeline →. With Roche-Genentech, Takeda.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
575actual
Sites
280
Countries
Argentina, Australia, Austria +24
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-10-19 | actual | When the study began enrolling |
| Primary completion | 2024-04-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-16 | estimated | The whole study's end, after follow-up |
| First posted | 2020-06-24 | actual | When this record first appeared on the registry |
| Results posted | 2025-12-18 | actual | When the sponsor posted results to the registry |
| Record updated | 2025-12-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Metastatic Prostate Cancer
- Prostate Adenocarcinoma
Interventions
- Drug: Cabozantinib — also filed as XL184, Cabometyx®
- Drug: Atezolizumab — also filed as Tecentriq®
- Drug: Abiraterone Acetate — also filed as Abiraterone, Zytiga
- Drug: Enzalutamide — also filed as Xtandi
- Drug: Prednisone
Primary outcomes
what the primary-completion date above is the date OFDuration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC)
measured Up to a maximum of approximately 30 months (Median duration of follow-up was 14.31 months)
Duration of Overall Survival (OS)
measured Up to a maximum of approximately 45 months (Median duration of follow-up was 24.05 months)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2023-01-24 · 3.2 MB · Prot_000.pdf
Statistical Analysis Planposted 2023-08-09 · 4.5 MB · SAP_001.pdf
Publications
- PMID 40523369 — linked by the registry
- PMID 35034502 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · EXEL's whole pipeline · Catalyst calendar · Every registered study · What changed